Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.Journal of cellular physiology · 2020
   Pooled it
2. MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.Frontiers in oncology · 2023
   Article
3. Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.Journal of immunology research · 2020
   Review
4. Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis.Journal of Cancer · 2020
   Article
5. miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2.Molecular therapy. Nucleic acids · 2019
   Article
6. Suicide among cancer patients: adolescents and young adult (AYA) versus all-age patients.Annals of translational medicine · 2019
   Article
7. The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer.Journal of thoracic disease · 2019
   Article

Corrections and comments

• Comment on
  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as